Skip to main content

Advertisement

SpringerLink
Log in

Update on immune reconstitution inflammatory syndrome: Progress and unanswered questions

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The immune reconstitution inflammatory syndrome (IRIS) is characterized by clinical deterioration occurring after the initiation of effective antiretroviral therapy (ART) and results from a disordered and exuberant immune response. The syndrome may present as paradoxical IRIS or unmasking IRIS, depending on whether an opportunistic infection was recognized and treated before ART initiation. Numerous descriptions of IRIS caused by many pathogens were published in the years after the introduction of effective ART. In recent years, with enhanced rollout of ART in resource-limited settings, attention has again focused on IRIS because of the enormous burden of opportunistic infections. This review highlights recent findings elucidating risk factors for and the pathogenesis and treatment of IRIS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Walensky RP, Paltiel AD, Losina E, et al.: The survival benefits of AIDS treatment in the United States. J Infect Dis 2006, 194:11–19.

    Article  PubMed  Google Scholar 

  2. Shelburne SA, Montes M, Hamill RJ: Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006, 57:167–170.

    Article  CAS  PubMed  Google Scholar 

  3. Lawn SD, Wilkinson RJ, Lipman MC, Wood R: Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008, 177:680–685.

    Article  PubMed  Google Scholar 

  4. Manabe YC, Breen R, Perti T, et al.: Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009, 199:437–444.

    Article  PubMed  Google Scholar 

  5. Meintjes G, Lawn SD, Scano F, et al.: Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516–523.

    Article  PubMed  Google Scholar 

  6. Colebunders R, John L, Huyst V, et al.: Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006, 10:946–953.

    CAS  PubMed  Google Scholar 

  7. Meintjes G, Rangaka MX, Maartens G, et al.: Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009, 48:667–676.

    Article  PubMed  Google Scholar 

  8. Bicanic T, Harrison T, Niepieklo A, et al.: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006, 43:1069–1073.

    Article  CAS  PubMed  Google Scholar 

  9. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ: Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418–427.

    Article  CAS  PubMed  Google Scholar 

  10. Murdoch DM, Venter WD, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008, 22:601–610.

    Article  CAS  PubMed  Google Scholar 

  11. Shelburne SA, Visnegarwala F, Darcourt J, et al.: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19:399–406.

    Article  PubMed  Google Scholar 

  12. French MA, Lenzo N, John M, et al.: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1:107–115.

    Article  CAS  PubMed  Google Scholar 

  13. Jevtovic DJ, Salemovic D, Ranin J, et al.: The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005, 6:140–143.

    Article  CAS  PubMed  Google Scholar 

  14. Manabe YC, Campbell JD, Sydnor E, Moore RD: Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007, 46:456–462.

    Article  CAS  PubMed  Google Scholar 

  15. Bicanic T, Meintjes G, Rebe K, et al.: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009, 51:130–134.

    Article  CAS  PubMed  Google Scholar 

  16. Lawn SD, Myer L, Bekker LG, Wood R: Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335–341.

    Article  PubMed  Google Scholar 

  17. Shelburne SA 3rd, Darcourt J, White AC Jr, et al.: The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:1049–1052.

    Article  PubMed  Google Scholar 

  18. Zolopa A, Andersen J, Powderly W, et al.: Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009, 4:e5575.

    Article  PubMed  CAS  Google Scholar 

  19. Karim S, Naidoo K, Grobler A, et al.: Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-coinfected patients in South Africa [abstract 36a]. Presented at 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.

  20. Kestens L, Seddiki N, Bohjanen PR: Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS 2008, 3:419–424.

    Article  PubMed  Google Scholar 

  21. French MA, Price P, Stone SF: Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615–1627.

    Article  CAS  PubMed  Google Scholar 

  22. Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361–373.

    Article  PubMed  Google Scholar 

  23. Phillips P, Bonner S, Gataric N, et al.: Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005, 41:1483–1497.

    Article  PubMed  Google Scholar 

  24. French MA, Mallal SA, Dawkins RL: Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992, 6:1293–1297.

    Article  CAS  PubMed  Google Scholar 

  25. Bourgarit A, Carcelain G, Martinez V, et al.: Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006, 20:F1–F7.

    Article  CAS  PubMed  Google Scholar 

  26. Tan DB, Yong YK, Tan HY, et al.: Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 2008, 9:307–316.

    Article  CAS  PubMed  Google Scholar 

  27. Ruhwald M, Ravn P: Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 2007, 21:882–884.

    Article  PubMed  Google Scholar 

  28. French MA: The immunopathogenesis of mycobacterial immune restoration disease. Lancet Infect Dis 2006, 6:461–462.

    Article  PubMed  Google Scholar 

  29. Van den Bergh R, Vanham G, Raes G, et al.: Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis 2006, 6:2–3; author reply 4–5.

    Article  PubMed  Google Scholar 

  30. Seddiki N, Kelleher AD: Regulatory T cells in HIV infection: who’s suppressing what? Curr Infect Dis Rep 2008, 10:252–258.

    Article  PubMed  Google Scholar 

  31. Seddiki N, Sasson SC, Santner-Nanan B, et al.: Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009, 39:391–403.

    Article  CAS  PubMed  Google Scholar 

  32. Meintjes G, Wilkinson KA, Rangaka MX, et al.: Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008, 178:1083–1089.

    Article  CAS  PubMed  Google Scholar 

  33. Tran DQ, Ramsey H, Shevach EM: Induction of FOXP3 expression in naive human CD4+ FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983–2990.

    Article  CAS  PubMed  Google Scholar 

  34. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S: Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 2007, 45:595–596.

    Article  PubMed  Google Scholar 

  35. Karavellas MP, Azen SP, MacDonald JC, et al.: Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001, 21:1–9.

    Article  CAS  PubMed  Google Scholar 

  36. Kempen JH, Min YI, Freeman WR, et al.: Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006, 113:684–694.

    Article  PubMed  Google Scholar 

  37. Fox PA, Barton SE, Francis N, et al.: Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999, 1:10–18.

    Article  CAS  PubMed  Google Scholar 

  38. Domingo P, Torres OH, Ris J, Vazquez G: Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001, 110:605–609.

    Article  CAS  PubMed  Google Scholar 

  39. Stone SF, Price P, French MA: Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease. J Antimicrob Chemother 2006, 57:585–588.

    Article  CAS  PubMed  Google Scholar 

  40. Price P, Morahan G, Huang D, et al.: Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043–2047.

    Article  CAS  PubMed  Google Scholar 

  41. Stone SF, Price P, Tay-Kearney ML, French MA: Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002, 185:1813–1817.

    Article  CAS  PubMed  Google Scholar 

  42. Stone SF, Price P, Brochier J, French MA: Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001, 184:1073–1077.

    Article  CAS  PubMed  Google Scholar 

  43. Schrier RD, Song MK, Smith IL, et al.: Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006, 26:165–169.

    Article  PubMed  Google Scholar 

  44. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.

    Article  CAS  PubMed  Google Scholar 

  45. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895–2902.

    Article  Google Scholar 

  46. John M, Flexman J, French MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289–2293.

    Article  CAS  PubMed  Google Scholar 

  47. Cicconi P, Cozzi-Lepri A, Phillips A, et al.: Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007, 21:599–606.

    Article  CAS  PubMed  Google Scholar 

  48. Matthews GV, Avihingsanon A, Lewin SR, et al.: A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008, 48:1062–1069.

    Article  CAS  PubMed  Google Scholar 

  49. Crane M, Oliver B, Matthews G, et al.: Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009, 199:974–981.

    Article  CAS  PubMed  Google Scholar 

  50. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 2009.

  51. Lewin SR, Ribeiro RM, Avihingsanon A, et al.: Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009, 49:1113–1121.

    Article  CAS  PubMed  Google Scholar 

  52. Simon V, Ho DD: HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 2003, 1:181–190.

    Article  CAS  PubMed  Google Scholar 

  53. Safdar A, Rubocki RJ, Horvath JA, et al.: Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002, 35:1250–1257.

    Article  PubMed  Google Scholar 

  54. Falco V, Olmo M, del Saz SV, et al.: Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008, 49:26–31.

    Article  PubMed  Google Scholar 

  55. Hoffmann C, Horst HA, Albrecht H, Schlote W: Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003, 74:1142–1144.

    Article  CAS  PubMed  Google Scholar 

  56. Giudici B, Vaz B, Bossolasco S, et al.: Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000, 30:95–99.

    Article  CAS  PubMed  Google Scholar 

  57. Miralles P, Berenguer J, Lacruz C, et al.: Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001, 15:1900–1902.

    Article  CAS  PubMed  Google Scholar 

  58. Crum NF, Ganesan A, Johns ST, Wallace MR: Graves disease: an increasingly recognized immune reconstitution syndrome. AIDS 2006, 20:466–469.

    Article  PubMed  Google Scholar 

  59. Foulon G, Wislez M, Naccache JM, et al.: Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:418–425.

    Article  PubMed  Google Scholar 

  60. Chen F, Day SL, Metcalfe RA, et al.: Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005, 84:98–106.

    Article  CAS  Google Scholar 

  61. French MA, Lewin SR, Dykstra C, et al.: Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses 2004, 20:157–162.

    Article  CAS  PubMed  Google Scholar 

  62. Tan K, Roda R, Ostrow L, et al.: PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009, 72:1458–1464.

    Article  CAS  PubMed  Google Scholar 

  63. Meintjes G, Wilkinson R, Morroni C, et al.: Randomized placebo-controlled trial of prednisone for the TB immune reconstitution inflammatory syndrome [abstract 34]. Presented at 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8–11, 2009.

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Disease, Department of Medicine, Emory University School of Medicine, 341 Ponce de Leon Avenue, Atlanta, GA, 30308, USA

    Wendy S. Armstrong

Authors
  1. Colleen F. Kelley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wendy S. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy S. Armstrong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelley, C.F., Armstrong, W.S. Update on immune reconstitution inflammatory syndrome: Progress and unanswered questions. Curr Infect Dis Rep 11, 486–493 (2009). https://doi.org/10.1007/s11908-009-0070-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-009-0070-y

Keywords

Search

Navigation